 Home > Medical News > Latest Medical News > The first in China!

The first in China!

 Last Update: 2022-01-01
 Source: Internet
 Author: User

Tags

stages cell signaling

anti histone antibody

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Article source: Medical Rubik's Cube Info

On December 3, Junshi Biological issued an announcement stating that the clinical trial application of JS009 injection was accepted by CDE, which is mainly used for the treatment of advanced malignant tumors

CD112R, also known as PVRIG (poliomyelitis virus receptor-associated immunoglobulin domain), is a single transmembrane protein of the PVR family.

JS009 can specifically bind to CD112R with high affinity, effectively blocking the signaling pathway of CD112R and its ligand CD112, thereby promoting the activation and proliferation of T cells and NK cells, and enhancing the immune system's ability to kill tumor cells

TIGIT is another immunosuppressive target of the PVR family.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.